Axer-Siegel Ruth, Herscovici Zvi, Hasanreisoglu Murat, Kremer Israel, Benjamini Yoav, Snir Moshe
Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.
Curr Eye Res. 2009 Aug;34(8):660-5. doi: 10.1080/02713680903007154.
To study the effect of intravitreal bevacizumab (Avastin) on the structure and growth of the young rabbit eye.
Twelve 6-week-old rabbits underwent intravitreal injection of bevacizumab (1.25 mg/0.05 ml) in one eye and no injection in the other (study group). Six additional rabbits served as controls. Slit lamp examination, fundus evaluation, and measurements of corneal power, central corneal thickness, corneal astigmatism, and axial length were performed before treatment and 1, 2, and 3 months after. At 3 months, the rabbits were sacrificed for histological study.
Within the study group, there were no significant differences in clinical parameters between the bevacizumab-treated and fellow eyes at any timepoint or overall. The estimated confidence intervals extended to about one standard deviation of their respective values. Comparison of the injected eyes in the study group with the uninjected eyes in the control group yielded similar findings. There were no between-group differences in ocular growth and no abnormalities of the anterior and posterior segments or the retina and retinal vasculature.
Intravitreal bevacizumab apparently has no adverse effect on the growth and development of the young rabbit eye, in a biologically or statistically significant way.
研究玻璃体内注射贝伐单抗(阿瓦斯汀)对幼兔眼睛结构和生长的影响。
12只6周龄兔子,一只眼睛接受玻璃体内注射贝伐单抗(1.25毫克/0.05毫升),另一只眼睛不注射(研究组)。另外6只兔子作为对照。在治疗前以及治疗后1、2和3个月进行裂隙灯检查、眼底评估,并测量角膜屈光度、中央角膜厚度、角膜散光和眼轴长度。3个月时,处死兔子进行组织学研究。
在研究组中,接受贝伐单抗治疗的眼睛与对侧眼睛在任何时间点或总体上,临床参数均无显著差异。估计的置信区间扩展到各自值的约一个标准差。研究组中注射药物的眼睛与对照组中未注射药物的眼睛比较,结果相似。眼生长方面无组间差异,眼前段和后段、视网膜及视网膜血管均无异常。
玻璃体内注射贝伐单抗对幼兔眼睛的生长和发育显然没有生物学或统计学上的显著不良影响。